A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Norihiro Nishimoto, Nobuyuki Miyasaka, Takayuki Sumida, Yoshihito Shima, Kazuki Takada, Isao Matsumoto, Kazuyoshi Saito, Takao Koike

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Although corticosteroids and immunosuppressants are widely used for the treatments of systemic lupus erythematosus (SLE), safer and more effective therapies are prerequisite. We and others have reported that anti-CD20 antibody rituximab targeting B cells are effective for refractory SLE and, therefore, safety and clinical efficacy of rituximab in SLE was evaluated by a multicenter phase I/II clinical trial. An open-label, multicenter study of 15 patients with active and refractory SLE (total British Isles Lupus Assessment Group [BILAG] score 8 to 17) was conducted. Rituximab was administered to 5 SLE patients as 4 infusions of 500 mg/body every week and to 10 SLE patients as 2 infusions of 1000 mg/body every other week. Assessment of safety, infusion reactions and adverse effects was used as the primary outcome for clinical tolerability and was evaluated by 28 weeks. Rituximab was well tolerated, with most experiencing no significant adverse effects. B cells rapidly reduced in all patients and remained low until 6 months post-treatment. Four patients developed human antichimeric antibodies without affecting efficacy of rituximab. Changes in routine safety laboratory tests clearly related to rituximab were not observed. Nine among 14 evaluable patients achieved the major or partial clinical response of BILAG score and prednisolone dose significantly decreased at the 28 weeks. Rituximab therapy appears to be safe for the treatment of active SLE patients and holds significant therapeutic promise, at least for the majority of patients experiencing profound B-cell depletion.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalModern Rheumatology
Volume17
Issue number3
DOIs
Publication statusPublished - 2007 Jun
Externally publishedYes

Fingerprint

Systemic Lupus Erythematosus
B-Lymphocytes
Safety
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Rituximab
Immunosuppressive Agents
Prednisolone
Multicenter Studies
Anti-Idiotypic Antibodies
Adrenal Cortex Hormones
Antibodies

Keywords

  • B cells
  • CD20
  • Monoclonal antibody
  • Rituximab
  • Systemic lupus erythematosus (SLE)

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Tanaka, Y., Yamamoto, K., Takeuchi, T., Nishimoto, N., Miyasaka, N., Sumida, T., ... Koike, T. (2007). A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Modern Rheumatology, 17(3), 191-197. https://doi.org/10.1007/s10165-007-0565-z

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. / Tanaka, Yoshiya; Yamamoto, Kazuhiko; Takeuchi, Tsutomu; Nishimoto, Norihiro; Miyasaka, Nobuyuki; Sumida, Takayuki; Shima, Yoshihito; Takada, Kazuki; Matsumoto, Isao; Saito, Kazuyoshi; Koike, Takao.

In: Modern Rheumatology, Vol. 17, No. 3, 06.2007, p. 191-197.

Research output: Contribution to journalArticle

Tanaka, Y, Yamamoto, K, Takeuchi, T, Nishimoto, N, Miyasaka, N, Sumida, T, Shima, Y, Takada, K, Matsumoto, I, Saito, K & Koike, T 2007, 'A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus', Modern Rheumatology, vol. 17, no. 3, pp. 191-197. https://doi.org/10.1007/s10165-007-0565-z
Tanaka, Yoshiya ; Yamamoto, Kazuhiko ; Takeuchi, Tsutomu ; Nishimoto, Norihiro ; Miyasaka, Nobuyuki ; Sumida, Takayuki ; Shima, Yoshihito ; Takada, Kazuki ; Matsumoto, Isao ; Saito, Kazuyoshi ; Koike, Takao. / A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. In: Modern Rheumatology. 2007 ; Vol. 17, No. 3. pp. 191-197.
@article{f74018c3c11f4c3b8749290315721f2d,
title = "A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus",
abstract = "Although corticosteroids and immunosuppressants are widely used for the treatments of systemic lupus erythematosus (SLE), safer and more effective therapies are prerequisite. We and others have reported that anti-CD20 antibody rituximab targeting B cells are effective for refractory SLE and, therefore, safety and clinical efficacy of rituximab in SLE was evaluated by a multicenter phase I/II clinical trial. An open-label, multicenter study of 15 patients with active and refractory SLE (total British Isles Lupus Assessment Group [BILAG] score 8 to 17) was conducted. Rituximab was administered to 5 SLE patients as 4 infusions of 500 mg/body every week and to 10 SLE patients as 2 infusions of 1000 mg/body every other week. Assessment of safety, infusion reactions and adverse effects was used as the primary outcome for clinical tolerability and was evaluated by 28 weeks. Rituximab was well tolerated, with most experiencing no significant adverse effects. B cells rapidly reduced in all patients and remained low until 6 months post-treatment. Four patients developed human antichimeric antibodies without affecting efficacy of rituximab. Changes in routine safety laboratory tests clearly related to rituximab were not observed. Nine among 14 evaluable patients achieved the major or partial clinical response of BILAG score and prednisolone dose significantly decreased at the 28 weeks. Rituximab therapy appears to be safe for the treatment of active SLE patients and holds significant therapeutic promise, at least for the majority of patients experiencing profound B-cell depletion.",
keywords = "B cells, CD20, Monoclonal antibody, Rituximab, Systemic lupus erythematosus (SLE)",
author = "Yoshiya Tanaka and Kazuhiko Yamamoto and Tsutomu Takeuchi and Norihiro Nishimoto and Nobuyuki Miyasaka and Takayuki Sumida and Yoshihito Shima and Kazuki Takada and Isao Matsumoto and Kazuyoshi Saito and Takao Koike",
year = "2007",
month = "6",
doi = "10.1007/s10165-007-0565-z",
language = "English",
volume = "17",
pages = "191--197",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

AU - Tanaka, Yoshiya

AU - Yamamoto, Kazuhiko

AU - Takeuchi, Tsutomu

AU - Nishimoto, Norihiro

AU - Miyasaka, Nobuyuki

AU - Sumida, Takayuki

AU - Shima, Yoshihito

AU - Takada, Kazuki

AU - Matsumoto, Isao

AU - Saito, Kazuyoshi

AU - Koike, Takao

PY - 2007/6

Y1 - 2007/6

N2 - Although corticosteroids and immunosuppressants are widely used for the treatments of systemic lupus erythematosus (SLE), safer and more effective therapies are prerequisite. We and others have reported that anti-CD20 antibody rituximab targeting B cells are effective for refractory SLE and, therefore, safety and clinical efficacy of rituximab in SLE was evaluated by a multicenter phase I/II clinical trial. An open-label, multicenter study of 15 patients with active and refractory SLE (total British Isles Lupus Assessment Group [BILAG] score 8 to 17) was conducted. Rituximab was administered to 5 SLE patients as 4 infusions of 500 mg/body every week and to 10 SLE patients as 2 infusions of 1000 mg/body every other week. Assessment of safety, infusion reactions and adverse effects was used as the primary outcome for clinical tolerability and was evaluated by 28 weeks. Rituximab was well tolerated, with most experiencing no significant adverse effects. B cells rapidly reduced in all patients and remained low until 6 months post-treatment. Four patients developed human antichimeric antibodies without affecting efficacy of rituximab. Changes in routine safety laboratory tests clearly related to rituximab were not observed. Nine among 14 evaluable patients achieved the major or partial clinical response of BILAG score and prednisolone dose significantly decreased at the 28 weeks. Rituximab therapy appears to be safe for the treatment of active SLE patients and holds significant therapeutic promise, at least for the majority of patients experiencing profound B-cell depletion.

AB - Although corticosteroids and immunosuppressants are widely used for the treatments of systemic lupus erythematosus (SLE), safer and more effective therapies are prerequisite. We and others have reported that anti-CD20 antibody rituximab targeting B cells are effective for refractory SLE and, therefore, safety and clinical efficacy of rituximab in SLE was evaluated by a multicenter phase I/II clinical trial. An open-label, multicenter study of 15 patients with active and refractory SLE (total British Isles Lupus Assessment Group [BILAG] score 8 to 17) was conducted. Rituximab was administered to 5 SLE patients as 4 infusions of 500 mg/body every week and to 10 SLE patients as 2 infusions of 1000 mg/body every other week. Assessment of safety, infusion reactions and adverse effects was used as the primary outcome for clinical tolerability and was evaluated by 28 weeks. Rituximab was well tolerated, with most experiencing no significant adverse effects. B cells rapidly reduced in all patients and remained low until 6 months post-treatment. Four patients developed human antichimeric antibodies without affecting efficacy of rituximab. Changes in routine safety laboratory tests clearly related to rituximab were not observed. Nine among 14 evaluable patients achieved the major or partial clinical response of BILAG score and prednisolone dose significantly decreased at the 28 weeks. Rituximab therapy appears to be safe for the treatment of active SLE patients and holds significant therapeutic promise, at least for the majority of patients experiencing profound B-cell depletion.

KW - B cells

KW - CD20

KW - Monoclonal antibody

KW - Rituximab

KW - Systemic lupus erythematosus (SLE)

UR - http://www.scopus.com/inward/record.url?scp=34250631349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250631349&partnerID=8YFLogxK

U2 - 10.1007/s10165-007-0565-z

DO - 10.1007/s10165-007-0565-z

M3 - Article

C2 - 17564773

AN - SCOPUS:34250631349

VL - 17

SP - 191

EP - 197

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 3

ER -